Related Experiment Videos
Androgen trial in renal anaemia
Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
|January 1, 1978
Summary
Nandrolone decanoate improved patient well-being in end-stage renal disease anemia but did not significantly raise hemoglobin levels. Subjective benefits like increased energy were noted, alongside side effects such as voice changes and hirsutism.
Area of Science:
- Nephrology
- Endocrinology
- Hematology
Background:
- Patients with end-stage renal disease (ESRD) often suffer from anemia.
- Anemia in ESRD is frequently treated with erythropoiesis-stimulating agents.
- The role of anabolic steroids in managing anemia in ESRD requires further investigation.
Purpose of the Study:
- To evaluate the efficacy of Nandrolone decanoate in treating anemia in patients with ESRD on hemodialysis.
- To assess the impact of Nandrolone decanoate on hemoglobin concentration, red cell mass, and erythropoietin levels.
- To document subjective patient-reported outcomes and adverse effects.
Main Methods:
- A double-blind, cross-over trial was conducted.
- 27 patients with ESRD on regular hemodialysis were enrolled.
- 16 patients completed the study, with others excluded due to side effects or other reasons.
Main Results:
- No sustained significant increase in hemoglobin or red cell mass was observed.
- Erythropoietin levels remained unchanged, within or below normal ranges.
- A majority of patients reported improved well-being, exercise tolerance, appetite, and libido.
- Adverse effects included voice changes, hirsutism, anticoagulant instability, and liver function abnormalities.
Conclusions:
- Nandrolone decanoate may offer subjective benefits for patients with ESRD-related anemia.
- These benefits, including improved well-being, appear unrelated to objective laboratory measurements.
- Lower dosages might achieve similar subjective improvements with potentially fewer side effects.